Disease Models & Mechanisms

Disease Models & Mechanisms is the fully open access biomedical journal of the non-profit Company of Biologists, founded in July 2008 in Cambridge, England, dedicated to using model systems to advance understanding, diagnosis and therapy of human disease, with a 2025 impact factor of 3.6.（Disease Models & Mechanisms）是英国剑桥非营利机构 The Company of Biologists 于 2008 年七月创刊的全开放获取生物医学刊，致力于以模式系统推进对人类疾病的理解、诊断与治疗，2025 年影响因子为 3.6。

Scope

• It publishes original research, resources and commissioned reviews focused on the use of model systems to better understand, diagnose and treat human disease.刊载原创研究、资源与特邀综述，聚焦使用模型系统更好地理解、诊断与治疗人类疾病。
• It is interdisciplinary in scope and covers a diverse range of diseases, methods and models, aiming to foster collaboration between basic and clinical researchers.其范围具跨学科性质，涵盖广泛的疾病、方法与模型，旨在推动基础与临床科研人员之间的合作。
• Disease areas include cancer, neurodegenerative and neurological disorders, psychiatric illness, metabolic disorders such as diabetes and obesity, and cardiovascular disease, stroke and hypertension.疾病方向包括癌症、神经变性与神经疾病、精神疾病、糖尿病与肥胖等代谢紊乱，以及心血管疾病、中风与高血压。
• They also include gastrointestinal disease, infectious disease, autoimmune and inflammatory conditions, developmental disorders, musculoskeletal disease, kidney and liver disease and eye disease.还包括胃肠疾病、传染病、自身免疫与炎症性疾病、发育性疾病、肌肉骨骼疾病、肾与肝疾病以及眼病。
• Model systems include mice, zebrafish, frogs and other vertebrates, invertebrates such as Drosophila and Caenorhabditis, stem cells, organoids and patient-derived models, and microorganisms such as yeast.模型系统包括小鼠、斑马鱼、蛙及其它脊椎动物，果蝇与线虫等无脊椎动物，干细胞、类器官与患者来源模型，以及酵母等微生物。
• Coverage also extends to drug and biomarker discovery and screening and to regenerative medicine and stem-cell therapies.还延伸至药物与生物标志物的发现和筛选，以及再生医学与干细胞疗法。

History

• It was founded in July 2008, and its first issue was a special inaugural issue.该刊创刊于 2008 年七月，第一期即为创刊特辑。
• It was initiated by Matthew Freeman and Daniel St Johnston, directors of the Company of Biologists, to foster a connection between model organism scientists and clinicians.由 The Company of Biologists 董事 Matthew Freeman 与 Daniel St Johnston 发起，旨在联通模式生物科学家与临床医生。^[1]
• Its first editor-in-chief was Vivian Siegel.首任主编为 Vivian Siegel。
• Monica J. Justice and Ross Cagan became senior editors in 2013, Justice served as editor-in-chief from 2016, and E. Elizabeth Patton was announced in December 2020 as the next editor-in-chief.2013 年 Monica J. Justice 与 Ross Cagan 成为资深编辑，Justice 自 2016 年起任主编，2020 年十二月宣布 E. Elizabeth Patton 为新任主编。^[2]
• It has had no change of name or publisher, being published by the Company of Biologists throughout.该刊无更名、无出版方变更，自创刊起始终由 The Company of Biologists 出版。^[3]
• It became the Company's first Gold Open Access journal in 2011, its print edition ended with volume 6 in 2013, and it now appears monthly, with a 2025 impact factor of 3.6 and a five-year impact factor of 4.2.2011 年成为该社首份金色开放获取期刊，纸版于 2013 年第 6 卷停刊，现按月出版，2025 年影响因子为 3.6，五年影响因子为 4.2。

Editors

• The editor-in-chief is E. Elizabeth (Liz) Patton of the MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, whose field is chemical genetics and zebrafish melanoma and cancer models.现任主编为 E. Elizabeth（Liz）Patton，任职于英国爱丁堡大学 MRC 人类遗传学单元、遗传学与癌症研究所，研究化学遗传学与斑马鱼黑色素瘤及癌症模型。
• The deputy or acting editor-in-chief is Ross Cagan of the Icahn School of Medicine at Mount Sinai in New York.代理主编为 Ross Cagan，任职于美国纽约西奈山伊坎医学院。
• Editors include Steven J. Clapcote, Tatsushi Igaki, Monica J. Justice, Rickie Patani, Owen Sansom and David Tobin, and the journal also has monitoring editors and an editorial board.编辑包括 Steven J. Clapcote、Tatsushi Igaki、Monica J. Justice、Rickie Patani、Owen Sansom 与 David Tobin，另设监测编辑与编委会。
• There are ten founding editors, appointed in 2008 and now serving as advisers, among them Gerard Evan, Mark C. Fishman, Susan L. Lindquist, Nadia Rosenthal, Janet Rossant, Allan Spradling, Tian Xu, Magdi Yacoub and Huda Zoghbi.2008 年设立十位创始编辑，现为顾问，包括 Gerard Evan、Mark C. Fishman、Susan L. Lindquist、Nadia Rosenthal、Janet Rossant、Allan Spradling、Tian Xu、Magdi Yacoub 与 Huda Zoghbi。
• Peer review is single anonymised, manuscripts are usually sent back with reports and a decision within about thirty days, and the journal uses cross-referee commenting.同行评审为单盲，送审稿件约三十天内返回评审报告与编辑决定，并采用审稿人交叉评议。
• It offers format-free submission, is preprint friendly with a bioRxiv link and uses continuous publication, and it awards an annual outstanding paper prize while running conference travel grants and travelling fellowships for early-career researchers.实行免格式投稿，与 bioRxiv 双向友好，采用连续出版，并设年度杰出论文奖，另为早期职业研究者提供会议旅费资助与访问奖学金。